Guidance Document for VCAs from Living Donors

VCA Committee June 2015

The Problem

- VCA included under OPTN Final Rule as "covered human organ"
- HHS: definition of VCA doesn't prohibit living VCA donation and OPTN has oversight over living VCA donation
- Numerous comments received for Fall 2014 VCA implementation proposal objected to inclusion of living VCA donors



Strategic Plan Alignment

Goal 5: Promote living donor safety

Provide guidance on living VCA donors

Proposed Solutions

 Guidance document to respond to public concern about living VCA donation and clear need for education

• Guidance document addresses:

- General considerations regarding VCA types that may be suitable to consider from living donors
- Criteria for living VCA recovery programs
- Recommendations on the informed consent and medical and psychosocial evaluation of living VCA donors

Collaboration with other committees

- Living Donor Committee
- Ethics Committee



Working Group

Sue McDiarmid, M.D. – transplant medicine, Chair VCA Committee

Scott Levin, M.D. – reconstructive surgery, Vice-Chair VCA Committee Rich Luskin, M.P.A. – organ procurement, Vice-Chair VCA Committee

Gerald Brandacher, M.D.

– reconstructive surgery,
VCA Committee

Bo Pomahac, M.D.– reconstructive surgery, VCA Committee

Mary Amanda Dew, Ph.D. – psychiatry, Chair Living Donor Committee Christie Thomas, M.D. – transplant medicine, Living Donor Committee

Krista Lentine, M.D.,
Ph.D. – transplant
medicine, Living Donor
Committee

Brad Kornfeld, J.D. –
OPTN Board member,
past member of Living
Donor Committee

Randy Schaffer, M.D. – transplant surgery, Living Donor Committee

Sanjay Kulkarni, M.D. – transplant surgery, Living Donor Committee Peter Reese, M.D. – transplant surgery, Chair Ethics Committee Elisa Gordon, Ph.D., M.P.H. – medical anthropology, Vice-Chair Ethics Committee



What Members will Need to Do

- Member transplant centers should reference the guidance document for:
 - Program recommendations
 - Recommendations for informed consent
 - Recommendations for medical and psychosocial evaluations



Overall Project Impact

Product

Guidance Document for VCAs from Living Donors

Target Population Impact:

Living Donors

Transplant Hospital and OPO staff

General Public

Total IT Implementation Hours

0/16,680



Total Overall Implementation Hours

30/23,685





Board Policy Group Recommendation

- 0-Approve without further discussion
- 1-Approve but discuss
- 1-Decline but discuss
- 7-No recommendation but discuss



Amendment 1

- Line 219
- Strike
- surrogacy and



Amendment 1

- Lines 232-236
- Strike
- Therefore, when the transplant team evaluates the risk-benefit ratio for the living VCA donor, it is critical to consider that the recipient may have other non-transplant options available. These might include use of autologous tissue, continuing to wait for a deceased VCA donor transplantation, prostheses, or adoption or surrogacy in the case of uterus transplantation.
- Insert
- Therefore, when the transplant team evaluates the risk-benefit ratio for the living VCA donor, it is critical to consider and discuss with the recipient and donor, that the recipient may have other non-transplant options available. These might include use of autologous tissue or continuing to wait for a deceased VCA donor.



Resolution 21 (page 98)

 RESOLVED, that the Guidance Document for VCAs from Living Donors, as set forth in Exhibit D of the VCA Committee's report to the Board, is hereby approved, effective June 2, 2015.

